Ratings by Morgan Stanley (Maxwell Skor)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/1/2026 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 8/21/2026 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/17/2026 | Monopar Therapeutics | MNPR | Maintain | Overweight (N/A) |
|
Details | ||
| 8/13/2026 | Achieve Life Sciences | ACHV | New Coverage | Overweight (N/A) |
6.77 (8.25) |
21.86% | Details | |
| 7/23/2026 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 6/25/2026 | Pharvaris B.V. | PHVS | Maintain | Overweight (N/A) |
|
Details | ||
| 6/11/2026 | CRISPR Therapeutics | CRSP | New Coverage | Equalweight (N/A) |
51.48 (56.82) |
10.37% | Details | |
| 5/6/2026 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 4/16/2026 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 4/8/2026 | Bicycle Therapeutics | BCYC | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/2/2026 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 3/30/2026 | Insmed | INSM | Upgrade | Overweight (Equalweight) |
147.60 (121.51) |
-17.68% | Details | |
| 3/17/2026 | Bicycle Therapeutics | BCYC | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/13/2026 | Sana Biotechnology | SANA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/2/2026 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 2/20/2026 | Insmed | INSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/12/2026 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 1/30/2026 | Insmed | INSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/9/2026 | Monopar Therapeutics | MNPR | New Coverage | Overweight (N/A) |
65.01 (117.57) |
80.85% | Details | |
| 12/23/2025 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 12/4/2025 | Pharvaris B.V. | PHVS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/17/2025 | Cidara Therapeutics | CDTX | Downgrade | Equalweight (Overweight) |
105.99 (221.38) |
108.87% | Details | |
| 11/14/2025 | Pharvaris B.V. | PHVS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2025 | Tscan Therapeutics Inc | TCRX | Downgrade | Equalweight (Overweight) |
1.19 (0.67) |
-43.7% | Details | |
| 10/31/2025 | Insmed | INSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/16/2025 | Cidara Therapeutics | CDTX | New Coverage | Overweight (N/A) |
110.64 (105.99) |
-4.2% | Details | |
| 8/20/2025 | Insmed | INSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/13/2025 | Insmed | INSM | Downgrade | Equalweight (Overweight) |
112.89 (147.60) |
30.75% | Details | |
| 7/17/2025 | Amicus Therapeutics | FOLD | Upgrade | Overweight (Equalweight) |
5.91 (14.49) |
145.18% | Details | |
| 7/3/2025 | Ascendis Pharma | ASND | New Coverage | Overweight (N/A) |
172.00 (260.25) |
51.31% | Details | |
| 7/3/2025 | Sana Biotechnology | SANA | New Coverage | Overweight (N/A) |
2.83 (3.83) |
35.34% | Details | |
| 5/8/2025 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 4/2/2025 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 3/7/2025 | Cytokinetics | CYTK | New Coverage | Overweight (N/A) |
43.27 (71.40) |
65.01% | Details | |
| 8/19/2024 | Invivyd Inc. | IVVD | Maintain | Overweight (N/A) |
|
Details | ||
| 3/26/2024 | Invivyd Inc. | IVVD | Upgrade | Overweight (Equalweight) |
4.36 (0.88) |
-79.82% | Details | |
| 12/7/2023 | Pharvaris B.V. | PHVS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2023 | Pharvaris B.V. | PHVS | Maintain | Overweight (N/A) |
|
Details | ||
| 9/25/2023 | Vaccitech | VACC | Downgrade | Equalweight (Overweight) |
1.69 (5.00) |
195.86% | Details | |
| 8/15/2023 | Pharvaris B.V. | PHVS | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/15/2023 | Pharvaris B.V. | PHVS | Upgrade | Overweight (Equalweight) |
18.56 (34.93) |
88.2% | Details |
